Eli Lilly Launches Targeted Cancer Drug Tanstrive in India
Eli Lilly and Company India has launched Tanstrive, a cancer drug approved by the Central Drugs Standard Control Organisation (CDSCO) for treating patients with locally advanced or metastatic solid tumors driven by RET gene alterations. Available in multiple tablet strengths and administered orally twice daily, Tanstrive targets abnormal signaling pathways to inhibit tumor growth. Priced at Rs 2.15 lakh per box for a 14-day regimen, the drug aims to expand access to precision oncology treatments in India, according to the company's president.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 32/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- economictimes— balanced framing, positive sentiment
- news18— balanced framing, positive sentiment
AI Analysis
The articles present a straightforward corporate announcement without political framing. Coverage focuses on the drug's approval, pricing, and therapeutic benefits, reflecting a neutral business and healthcare perspective. There is no evident political bias or partisan interpretation, as the sources relay company statements and regulatory information factually.
The tone across the articles is neutral to positive, emphasizing the drug's approval and potential benefits for cancer patients. The coverage highlights advancements in precision oncology and expanded treatment options without critical or negative commentary, maintaining an informative and optimistic sentiment.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.